Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.555
-0.005 (-0.32%)
Mar 14, 2025, 12:33 PM EDT - Market open
Aclaris Therapeutics Employees
As of December 31, 2024, Aclaris Therapeutics had 64 total employees, including 61 full-time and 3 part-time employees. The number of employees decreased by 27 or -29.67% compared to the previous year.
Employees
64
Change (1Y)
-27
Growth (1Y)
-29.67%
Revenue / Employee
$292,500
Profits / Employee
-$2,063,516
Market Cap
167.81M
Employees Chart
ACRS News
- 10 days ago - Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewsWire
- 4 weeks ago - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 3 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 4 months ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire